Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

the safety and

tolerability results of ITMN-191 were excellent.

-- That the trial had achieved its principal goals for viral kinetic

performance, safety and tolerability to advance the program into a

triple combination study with Pegasys(R) and ribavirin.

-- It expected to complete enrollment of the third dose cohort in the

MAD study in January 2008. InterMune announced today that

enrollment of that cohort was completed in late January and that

data from the third cohort are not yet available to the company.

-- InterMune expects to begin a 14-day triple combination study of

ITMN-191 with Pegasys(R) and ribavirin in the second quarter of

2008.

Guidance for 2008 Operating Expenses

InterMune today provided its forward-looking guidance with respect to operating expenses in 2008.

For the year ending December 31, 2008, R&D expense is anticipated to be similar to 2007 in a range of approximately $100 to $110 million, net of development cost reimbursements under the Roche collaboration. G&A expense is anticipated to be in a range of approximately $25 to $30 million.

Key Development Program Milestones

InterMune today noted the upcoming milestones with respect to its key development programs.

CAPACITY Program in IPF:

-- InterMune expects to announce top-line results of its Phase 3 CAPACITY

program in IPF in January of 2009.

ITMN-191 Program in HCV:

-- In conjunction with its partner, Roche, InterMune has decided to

complete a fourth cohort of the Phase 1b multiple-ascending-dose (MAD)

study to further inform the planned 14-day triple therapy study and

potential direct anti-viral combination studies in the future.

Consequently, InterMune has decided to announce results from the first

four cohorts of the Phase lb MAD study
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... the consolidating pharmaceutical industry began. For those of you who ... were talking about the hostile bid by French pharmaceutical giant ... Aventis . , ,This would create a real major ... would create the worlds third-largest pharmaceutical company after No. 1 ...
... response, it looks as if Small Tree Communications ... group of former Cray and SGI employees to brave the ... Grove Heights, Minn.-based business, with ties to legacy Chippewa Valley ... breakthrough product for Apple Computers enterprise customers who need enhanced ...
... Madison, Wis., -- Broadjam Inc. , a Madison-based provider ... publishers, has been selected to create and implement a ground-breaking ... . , ,In an intriguing move from an industry often ... onto the Internet in time for its annual awards show ...
Cached Biology Technology:The Industry Impact of Two Big Pharmas Mating 2The Industry Impact of Two Big Pharmas Mating 3The Industry Impact of Two Big Pharmas Mating 4The Industry Impact of Two Big Pharmas Mating 5The Industry Impact of Two Big Pharmas Mating 6The Industry Impact of Two Big Pharmas Mating 7Former SGI/Cray Team Develops Products for G5 Platform 2Former SGI/Cray Team Develops Products for G5 Platform 3
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... Infinisource has launched its new NXG series of time clocks ... a higher standard for collecting attendance and labor data and ... installation, touch screen interface and seamless connection to cloud-based iSolved, ... solution for the small to mid-size employer. The ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2
... KNOXVILLE -- Research by a small group of microbiologists ... of the Earth: the realm just beneath the deep ocean ... on our planet. Beth Orcutt, a post-doctoral fellow at ... presented her new findings about this little researched realm today ...
... research studies should not be disclosed to participants without ... of the European Society of Human Genetics today (Monday). ... Policy, Management and Evaluation at the University of Toronto, ... held by many ethicists that individual genetic research findings ...
... Researchers at Rice University, Purdue University and the ... about why some fluids containing polymers -- including saliva ... do not. The findings are published online this ... Study co-author Matteo Pasquali, professor in chemical and biomolecular ...
Cached Biology News:New research into the deep ocean floor yields promising results for microbiologists 2Should the results of individual genetic studies be disclosed to participants? 2Should the results of individual genetic studies be disclosed to participants? 3Answer to saliva mystery has practical impact 2
... A thermostable, thermoactive designer enzyme ... single-tube-reaction. AccuRT RNA PCR enzyme allows ... be performed at elevated temperatures (65C), ... from the template and results in ...
HLA-DRbeta (DA2)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
... polyclonal NPY Y2 Receptor antiserum This ... the spinal level and is currently being characerized ... both rat and mouse and appears to work ... seen in rat. For full characterizarion in dorsal ...
Biology Products: